Barinthus Biotherapeutics

BRNS | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.74

-$0.02 (-2.50%)

Sep 8, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Key Executives

Name	Position
William J. Enright	Chief Executive Officer & Director
Douglas J. Swirsky	CFO & Principal Accounting Officer
Leon Hooftman	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Sep 01, 2026	8-K	Current Report
Aug 25, 2026	8-K	Current Report
Aug 06, 2026	8-K	Current Report
Aug 06, 2026	10-Q	Quarterly Report
Jul 02, 2026	8-K	Current Report
Jun 10, 2026	ARS	Filing
Jun 10, 2026	DEF 14A	Filing
May 21, 2026	8-K	Current Report
May 01, 2026	3	Filing
Apr 30, 2026	10-Q	Quarterly Report

View All SEC Filings ➞

Barinthus Biotherapeutics

Country	United States
IPO Date	Apr 29, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	William James Enright

Contact Details

20400 Century Boulevard Germantown, Maryland 20874 United States

https://www.barinthusbio.com

44 1865 818 808

Stock Details

Ticker Symbol	BRNS
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001828185
CUSIP Number	91864C107
ISIN Number	US91864C1071
SIC Code	2834